Medtronic: "No delay" to CoreValve's US approval despite trial redesign
This article was originally published in Clinica
Executive Summary
US approval of Medtronic's CoreValve transcatheter aortic heart valve is still expected in 2014, the company has confirmed. Medtronic is to modify its pivotal US trial of the valve, but the firm told Clinica that this would not delay the valve's passage to US approval.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.